Reprise Biomedical, Inc. filed an amended Form D with the Securities and Exchange Commission on 2026-05-21.
Reprise Biomedical, Inc. filed an amended Form D notice of an exempt securities offering with the SEC on May 21, 2026. The filing reports $9.25M sold. Its industry group is Biotechnology. It names Carrie Powers (Executive Officer, Director), Jake Isenburg (Executive Officer), Tom Kouchoukos (Executive Officer) (SEC Form D/A, May 21, 2026).
125 companies raised this week.
Companies that just raised money, and the people to call. Before you unlock: the company, the amount, the date and what is inside (for example 2 people, phone, LinkedIn). After: the officers and directors the filing names with their roles, how to reach the company, and a person's email only when we found one.
| Andersen Aggregator LLC | $1.9B | Business services |
| AT Umbrella LLC | $1.9B | Business services |
| Legora, Inc. | $221M | AI and software |
| MD INVESTMENT LLC | $169M | Business services |
| Serval Inc. | $149M | AI and software |
Is this your company?
Sell to companies like Reprise Biomedical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-05-21 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Reprise Biomedical, Inc.
Free to see. No signup.
More on the people and the money behind Reprise Biomedical, Inc., from the filings we hold.
Cedar Point Capital, LLC received sales compensation on this raise and on 6 other raises we hold, nearest in date first:
Biotechnology raises filed within 90 days of this one, largest first.
Get an email when Reprise Biomedical, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Reprise Biomedical, Inc. raises, hires or launches. No email unless you switch it on.
Watch Reprise Biomedical, Inc. →Get the full cited report on Reprise Biomedical, Inc.
What the filing shows about Reprise Biomedical, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Reprise Biomedical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Reprise Biomedical, Inc.'s address as 17400 Medina Rd., Ste. 100, Plymouth, MN 55447.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Reprise Biomedical, Inc. →
Amended on 2026-07-01: the offering size changed from $8,000,000 to $10,000,000; the amount sold changed from $1,450,000 to $9,246,100; the number of investors changed from 4 to 43. Figures on this page are from the amendment. Amended filing · Original filing
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Reprise Biomedical, Inc. See pricing
Reprise Biomedical, Inc. is a registered filer with the SEC (CIK 1782236) and has filed since 2023-01-03. 4 filings are on record, the latest on 2026-05-21.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Reprise Biomedical, Inc.'s Form D of 2026-05-21 names Carrie Powers, Jake Isenburg, Tom Kouchoukos and 10 more as its officers, directors or promoters.
Its new offerings report $25.40M sold across 4 offerings, as its own filings state.
A hollow marker is an amendment (Form D/A); a solid one is an original Form D. The larger marker is the filing this page is about.
Trailing twelve months. 766 filings in Biotechnology, totalled by week. The dot is this raise, $9.25M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Checked away from the filing. What is below does not come from the record on sec.gov.
Developing biological medical devices that deliver solutions to unmet clinical needs of surgeons in wound care and soft tissue reinforcement.
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
Carrie Powers is named as Executive Officer and Director on the Form D that Reprise Biomedical, Inc. filed with the SEC on 21 May 2026, one of 13 people that filing names.
Jake Isenburg is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 21 May 2026, one of 13 people that filing names.
Tom Kouchoukos is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 21 May 2026, one of 13 people that filing names.
Steve Jagodzinski is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 21 May 2026, one of 13 people that filing names.
Greg Smock is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 21 May 2026, one of 13 people that filing names.
Jerrod Krueger is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 21 May 2026, one of 13 people that filing names.
Heather Kotila is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 21 May 2026, one of 13 people that filing names.
Howard Root is named as Director on the Form D that Reprise Biomedical, Inc. filed with the SEC on 21 May 2026, one of 13 people that filing names.
Ronald Eibensteiner is named as Director on the Form D that Reprise Biomedical, Inc. filed with the SEC on 21 May 2026, one of 13 people that filing names.
Erwin Kelen is named as Director on the Form D that Reprise Biomedical, Inc. filed with the SEC on 21 May 2026, one of 13 people that filing names.
Phil Nalbone is named as Director on the Form D that Reprise Biomedical, Inc. filed with the SEC on 21 May 2026, one of 13 people that filing names.
Alan Woldt is named as Director on the Form D that Reprise Biomedical, Inc. filed with the SEC on 21 May 2026, one of 13 people that filing names.
Jeff Duncan is named as Executive Officer on the Form D that Reprise Biomedical, Inc. filed with the SEC on 21 May 2026, one of 13 people that filing names.
13 people named on the filing — 8 holding an executive role and 5 as directors only.
Named as of the 2026-05-21 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
Of the 13 names on this filing, 12 are drawn here to keep the picture readable. The People tab lists them all.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Reprise Biomedical, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Reprise Biomedical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Reprise Biomedical, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Reprise Biomedical, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Reprise Biomedical, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-26 (reprisebio.com).
Each opens in a new tab, filled in for Reprise Biomedical, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Minneapolis-St. Paul
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/reprise-biomedical-inc-form-d-26000001